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Background: Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker 
associated with inflammatory and certain malignancies. Earlier we have shown that 
plasma suPAR (P-suPAR) predicts severity of acute alcohol-induced pancreatitis (AAP) on 
admission. Our aim was to investigate whether P-suPAR levels predict AAP recurrences 
or mortality during long-term follow-up after first AAP.   
Methods: Eighty-three patients (median age 47.5, range 25-71 years) suffering their first 
AAP during 2001-2005 were recruited and followed prospectively for 9 years with a 
median follow-up time of 7.0 (range 0.3-9.8) years. P-suPAR was measured by enzyme-
linked immunosorbent assay (ELISA) from the samples taken at follow-up visits. Survival 
was registered in November 2014.  
Results: P-suPAR level on admission or after recovery of the first AAP did not predict the 
recurrence of AAP. However, higher P-suPAR measured after recovery of first AAP (3.6 
vs. 2.9 ng/mL) predicted mortality during follow-up period (hazard ratio 1.48, p=0.008). 
Cut-off value for P-suPAR indicating a higher risk for 10-year mortality resulted a value of 
≥3.4 ng/mL. When adjusted for other covariates, P-suPAR above cut-off level retained its 
statistical significance as an independent factor. 
Conclusions: P-suPAR level on admission or after recovery of the first AAP does not 
predict the recurrence of AAP during long-term follow-up. However, P-suPAR ≥3.4 mg/mL 
measured after recovery from first AAP is associated with an increased risk of 10-year 
mortality as an independent factor. This can be used to detect patients with highest risk 
after AAP, in order to focus the preventive healthcare actions. 
Keywords: acute pancreatitis, alcohol-related diseases, inflammation, mortality, 
prevention, risk factors 
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INTRODUCTION 
Acute pancreatitis (AP) has an increasing incidence in Finland, and it has serious effects 
on the public health and health care costs. The major cause of AP is alcohol, which is 
responsible for 70% of the cases [1, 2]. The risk to develop a recurrent episode of acute 
pancreatitis (RAP) is high among these patients: after the first alcohol-induced AP (AAP) 
about half of the patients will develop a RAP. Recurrence pattern and risk factors 
concerning the recurrence after first AAP have been reported previously, and among 
patients developing RAP, 80% of patients had a recurrence during the first 4 years, and 
90% of patients during the first 6 years [3]. The known risk factors for RAP include 
continuing alcohol consumption and usage of sedative medication prior to first AAP 
episode [4]. In addition, younger age, smoking, obesity, pancreatic malfunction and milder 
first AAP are suggested to be risk factors for RAP, but the evidence is not distinct [3, 5]. 
Finding of individuals with the highest risk for RAP and mortality would help to focus the 
limited resources on these patients.  
Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker associated with 
inflammatory and certain malignant diseases. Circulating blood suPAR level reflects the 
activation level of overall human immune system [6] and serves as a marker for disease 
severity and increased risk for mortality [7]. Our group has recently reported that plasma 
suPAR (P-suPAR) levels are elevated in first AAP, and high P-suPAR at admission of AAP 
predicts a more severe disease [8]. 
Based on the promising results of P-suPAR predicting the severity of AAP at admission, 
we wanted to investigate whether P-suPAR also predicts the AAP recurrence or prognosis 
when measured on admission, after recovery and during the long-term follow-up after the 
first AAP. 
METHODS 
Eighty-three patients [median age 48 years (range 25-71 years); 90% male] with their first 
AAP treated in Tampere University Hospital during 2001-2005 formed the study 
population. Exclusion criterias were previous history of pancreatitis of other etiology of 
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pancreatitis. Follow-upwas based on voluntarism and required sufficient co-operation.. The 
severity of the first acute AAP was classified according the revised Atlanta criteria [9], and 
the moderately severe and severe grades were combined for the analysis as a non-mild 
group.  
The patients were prospectively followed up for 9 years, with a median follow-up time of 
7.0 (range 0.3-9.8) years. BMI, smoking (cigarettes per day), alcohol consumption (grams 
per week) and comorbidities such as diabetes and cardiovascular diseases (e.g. coronary 
disease, hypertension, hypercholesterolemia) were registered on admission, at 24 months 
(median, range 5-32 months) after recovery (after recovery sample, months from index 
admission), and during the long-term follow-up at 5, 7 and 9 years. Medical reports were 
reviewed to complete any missing data. P-suPAR values were retrospectively measured 
from plasma samples collected on control visits [3], and survival was registered in 
November 2014. Fully informed written consent was obtained from each patient, and the 
Ethics Committee of Tampere University Hospital, Finland approved the study protocol 
(decision number R00126). Demographic data is presented in Table 1. Drop out 
percentage was 33% in 5-year, 47% in 7-year, and 55% in 9-year control point. Survival 
data was available from all patients. 
Characteristics 
Gender (male/female) 75/8 (90%/10%) 
Age on admission, years, median (range) 48 (25-71) 
Follow-up time, months, median (range) 84 (18-117) 
Survival follow-up time, median, months (range) 138 (38-166) 
Death during follow-up time 19 (23%) 
Severity of first AAP (mild/non-mild) 55/28 (66%/34%)  
Recurrent pancreatitis during follow-up 32 (39%) 
Chronic pancreatitis 12 (14%) 
Diabetes mellitus 35 (42 %) 
BMI (kg/m-2), median on admission (range) 28 (19-38)
Smoking (cigarettes/day) 10 (0-50) 
Alcohol abuse (g/2 months)1 3048 (288-15456) 
Cardiovascular disease (HBP/CHD)2 16 (19%) 
5 
Malignancy 3 (4 %) 
1data missing on 1 patient 
2HBP = high blood pressure; CHD = coronary heart disease 
Table 1. Demographic and clinical characteristics of patients (n=83) recruited on 
admission of their first alcohol-induced pancreatitis (AAP). 
P-suPAR was measured by enzyme-linked immunosorbent assay (ELISA) from blood 
samples stored at -70°C using enzyme-linked immunosorbent assay (ELISA) according to 
manufacturer’s instructions (suPARnostic®, ViroGates A/S, Birkerød, Denmark).  
Statistical analysis was run with IBM SPSS Statistics for Windows (Version 22 and 23). 
Univariate analysis of P-suPAR values was performed by using Mann-Whitney U test as 
the data was not normally distributed. P-values ≤0.05 were considered significant. 10-year 
mortality was estimated using ROC curve analysis, and cut-off value was calculated using 
Youden’s J statistic. Survival curves were established with Kaplan-Meier method and 
differences were estimated with log rank test. Hazard ratio and multivariate analysis were 
established with COX regression analysis.  
RESULTS 
Among the 83 patients with their first AAP, pancreatitis was classified as mild in 66% 
(n=55), moderately severe in 28% (n=23) and severe in 6% (n=5). During the 9-year 
prospective follow-up, 39% (n=32) of the patients had at least one RAP, 14% (n=12) 
developed chronic pancreatitis and 23 % (n=19) died. Among the 19 patients who died, 
the median survival after the first AAP was 8 years (range 3.2-13.3 years) and median age 
in deceased patients was 60.6 years (range 44.1-76.0 years). The cause of death was 
registered in 14/19 patients, and was accidental in 7 (falling in 3, suffocation in 2, drowning 
in 1 and burning in 1 cases), malignancy in 3, intoxication in 2, gastrointestinal bleeding in 
1, acute pancreatitis in 1 and cardiac arrhythmia in 1 patient.  
P-suPAR level remained higher for 12 months after recovery in patients with a non-mild 
AAP compared to the patients with a mild AAP [median 3.7 (IQR 3.3-3.9) vs. 3.1 (2.6-3.6) 
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ng/mL, p=0.047]. However, two years after the first AAP no difference was seen between 
the non-mild and mild AAP patients [2.7 (2.3-3.3) vs. 2.9 (2.5-3.6) ng/mL; NS]. P-suPAR 
levels of the patients with 2 or more RAPs did not differ from the patients with 1 or no RAP 
at any time point. P-suPAR values on admission [4.5 (3.6-5.3) vs. 4.1 (3.1-6.2) ng/mL; NS] 
or after recovery of the first AAP [3.0 (2.6-3.8) vs. 3.1 (2.5-3.3) ng/mL; NS] did not differ 
between the patients with or without RAPs, respectively. 
 
P-suPAR level measured on first control visit after the first AAP was associated with 10-
year mortality, whereas P-suPAR level measured on admission or later during the follow-
up were not. In those patients who died during the follow-up, P-suPAR after recovery of 
the first AAP was significantly higher compared to the patients who survived [3.6 (2.7-4.1) 
vs. 2.9 (2.5-3.3) ng/mL; hazard ratio 1.48, p=0.008]. The cut-off value for P-suPAR 
indicating a higher risk for 10-year mortality was estimated using ROC curve analysis 
shown in Figure 1.  
 
 
Figure 1. ROC (receiver operating characteristics) curve for P-suPAR measured after 
recovery from the first acute AAP to evaluate mortality risk in 10 years. 
 
Area under the curve (AUC) was 0.75 (CI 0.61-0.89); p=0.002. Cut-off P-suPAR value 
calculated using Youden’s J statistic was 3.4 ng/mL with the sensitivity and specificity 
predicting long-term mortality of 58% and 82%, respectively. Patients were further divided 
into high or low level of P-suPAR after recovery of the first AAP (P-suPAR <3.4 ng/mL or 
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≥3.4 ng/mL), and Kaplan-Meier survival curves were established to indicate mortality 
(Figure 2). The risks for 10-year mortality for patients with P-suPAR <3.4 ng/mL or ≥3.4 
ng/mL were 13% and 49%, respectively. 
Figure 2. Cumulative survival in patients with P-suPAR after recovery ≥3.4 ng/mL and 
<3.4 ng/mL. Out of the 19 patients who died during the follow-up, 11 (58%) had the P-
suPAR value above the cut-off level 3.4 ng/mL. 
A multivariate analysis was performed to study other factors with a possible influence. 
Factors studied were smoking (tobaccos per day), BMI, existence of diabetes and 
cardiovascular diseases (coronary syndrome, high blood pressure and/or high blood 
cholesterol), age, gender and alcohol amount used (grams per week). Covariates and their 
hazard ratios are shown in table 2. When adjusted for all other covariates, P-suPAR above 
cut-off level retained its statistical significance. P-suPAR ≥3.4 mg/mL measured after 
recovery from first AAP was associated with increased risk of mortality (hazard ratio 4.14, 





Covariate HR (95% CI) 95% CI p-value 
P-suPAR ≥3.4 mg/mL 4.14 1.31-13.0 0.015 
BMI (kg/m-2) 0.90 0.75-1.07 0.210 
Smoking 0.77 0.16-3.70 0.740 
Age 1.05 0.99-1.12 0.111 
Cardiovascular disease 1.56 0.42-5.72 0.515 
diabetes mellitus (DM)    
  no DM 1.00   
  DM before 1. AAP 0.65  0.07-5.86 0.702 
  DM after AAP 0.87  0.25-2.99 0.818 
Alcohol consumptiona (kg/2 
months) 
1.12  0.97-1.30 0.116 
Recurrent AAP 2.44  0.76-7.79 0.133 
Chronic pancreatitis 3.19  0.77-13.2 0.108 
Severity of 1. AAP    
  Mild 1.00   
  Moderate 1.14  0.33-3.95 0.837 
  Severe 0.51  0.04-6.85 0.613 
adata available on 82/83 patients  
 
Table 2. Risk factors for mortality after recovery from first alcohol-induced pancreatitis 





Earlier studies have suggested that elevated suPAR level may be associated with poorer 
prognosis in gastrointestinal disorders [10, 11, 12, 13, 14]. Recently we have shown that 
elevated P-suPAR on admission predicts the severity of AAP [8]. In this study we went 
further to investigate whether P-suPAR measured on the first AAP admission, on its 
recovery or during follow-up could be used to identify those patients who are in a high risk 
9 
of developing RAP episodes or have a poorer long-term prognosis. To our knowledge no 
previously published data on suPAR about the long-term follow-up after AAP exists. We 
found that P-suPAR did not predict the RAP episodes but was able to detect the patients 
with a high risk for 10-year mortality. A cut-off value of 3,4 ng/mL after recovery of first 
AAP was an independent risk factor for long-term mortality. 
Urokinase plasminogen activator receptor (uPAR) is expressed by various immunologically 
active and inflammatory cells, such as monocytes, activated T-lymphocytes, macrophages 
and certain cancer cells. uPAR seems to be up-regulated in cells that are in motion, 
whereas cells that are lacking stimulus do not express uPAR [15]. In certain inflammatory 
conditions - after uPAR interaction with its urokinase plasminogen activator (uPA) ligand - 
uPAR is proteolytically cleaved by various kind of proteases from the cell surface to its 
soluble form suPAR, which can then be measured from blood, cerebrospinal fluid and 
urine [6]. About half of patients with continuous alcohol abuse after AAP develop a RAP. 
Our hypothesis was that the recurrent inflammatory episodes could be detected as 
permanently elevated P-suPAR levels. However, we found no significant difference 
between the patients with and without RAPs in short or long-term follow-up. Since 
smoking, morbid obesity >40 kg/m2, alcohol consumption, age, sex, history of 
cardiovascular diseases and many other factors are shown to have effect on P-suPAR 
levels [7], the possible differences caused by elevated pancreatic inflammation state in this 
population may not be detected. 
Elevated P-suPAR levels are associated with short-term (30-90 ‒day) mortality in many 
different inflammatory diseases, for example sepsis [16] as well as in heterogeneous 
medical patient population [17]. P-suPAR correlation with long-term mortality in general 
population has also been shown [18], and this data correlates with our findings. In our 
study the mortality rate is very high comparing to median age, showing that these patients 
have high risk to die young. Reasons of death were diverse, including intoxication, 
malignancies and trauma. It has been shown that suicidal and depressive patients have 
elevated P-suPAR levels, referring to an inflammatory background of depressive behavior 
[19]. People with alcohol abuse commonly persist depressive and high-risk behavior [20]. 
The accidental deaths, intoxications and pancretitis-associated death were regarded as 
related to alcohol abuse and thus could potentially be prevented. 
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Additional studies and larger study populations are needed to examine if P-suPAR levels 
could explain long-term mortality in other disease conditions as well, and if development of 
chronic pancreatitis could be predicted with P-suPAR level measurements. 
 
The severity of pancreatitis ranges from mild abdominal pain to life-threatening multi-organ 
failure (MOF) with mortality of 2-16%. The amount of alcohol used prior to first AAP is 
suggested to correlate with severity of AAP [21]. P-suPAR of patients with non-mild first 
AAP remains significantly higher than in patients with mild first AAP. This may be due to 
the longer healing process from a more severe disease. In two years after AAP, these 
levels become and stays even.  The  study cohort is estimated to  represent average 
patients after the first AAP.  
 
P-suPAR levels of these patients in follow-up samples are higher than in normal 
population measured in earlier studies [7, 18]. We do not know the P-suPAR levels of 
these patients before their first AAP. This study awakens the question, if P-suPAR levels 
after recovery from first AAP are a result from pancreatitis itself or reflect the overall 
inflammatory state of human body. Despite the initial cause of elevated P-suPAR, it is 
useful in identifying the crucial patients who are at high risk for mortality, needing an 
intervention and intensive follow-up after their first AAP.  
 
Limitations of this study include the lack of possibility to compare P-suPAR levels to 
general population, small patient number and the number of drop-outs over time. The 
association between suPAR-level and high accidental mortality rate is also difficult to 
interprete. There were a lot of drop-outs between 100-120 months in patients with low 
suPAR values. Whether the patients who are asymptomatic are less motivated to control 
visits than the ones with symptoms is not known. What we do know is that it is challenging 
to motivate patients with alcohol-related diseases for control visits. True amount of RAP 
episodes may differ from the reported, because of disease can be so mild that patients do 
not admit to hospital, or they may have been treated elsewhere. This patient data is, 
however, prospective, though P-suPAR -analyses are retrospective, and patients were 
interviewed for possible recurrent attacks so the amount of recurrences is regarded 
reliable. Previous use of sedative medication is shown to have effect on AAP recurrence 
[4]. Medication data of these patients was not reported, so this possible influence has not 
been evaluated. The strength of our study lies on prospective and long-time follow-up.   
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We conclude that P-suPAR level measured on admission or after recovery of the first AAP 
does not predict the RAP during the long-term follow-up. However, a high P-suPAR ≥3.4 
mg/mL measured after recovery from the first AAP is associated with an increased risk of 
10-year mortality as an independent factor. This may help to detect the patients with the 
highest risk after AAP, in order to focus the preventive healthcare actions to the ones in 
the greatest need, as well as to inform the patients about their prognosis and motivate 
them for a lifestyle change.  
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